PPARG and major depressive disorder: Namely, Sepanjnia et al. showed that pioglitazone, a selective PPAR-γ agonist, is an effective and safe short-term add-on therapy to Citalopram in non-diabetic patients with MDD and was associated with a high rate of early improvement and remission (194).